精美幻灯(美国临床肿瘤学会年会恶性血液病最新进展)（精品PPT）.ppt

* * * * * * * * * * * * * * Rituximab 375 mg/m2 d1 Gemcitabine 1000 mg/m2 d2 Oxaliplatin 100mg/m2 d2 * * * * * * * * * * * * * * * * * * * * * * * Concomitant therapy Aspirin dosed 81 mg or 325 mg daily for prevention of thrombosis Prophylaxis antiviral therapy for herpes zoster Management of peripheral neuropathy Bisphosphonates * * * DASISION: Differences in Adverse Events Rates With Dasatinib vs Imatinib Kantarjian H, et al. ASCO 2010. Abstract LBA6500. Reprinted with permission. -0.4 -0.2 0 0.2 0.4 Anemia, grade 3/4Neutropenia, grade 3/4Thrombocytopenia, grade 3/4Myalgia*NauseaVomitingRashDiarrheaFatigueHeadacheFluid retentionSuperficial edemaPleural effusion Rate difference (dasatinib-imatinib) with exact 95% CI Favors Dasatinib Favors Imatinib *Myalgia = myalgia, muscle inflammation, and MSK pains. Conclusions Dasatinib associated with superior efficacy compared with imatinib for first-line treatment of CP-CML Higher and faster rates of CCyR, confirmed CCyR, and MMR Dasatinib generally well tolerated Low rates of grade 3/4 hematologic toxicity Results support use of dasatinib as first-line therapy for patients with newly diagnosed CP-CML Kantarjian H, et al. ASCO 2010. Abstract LBA6500. Patients newly diagnosed withPh-positive CP-CML within 6 mos (N = 846) Nilotinib 300 mg BID (n = 282) Nilotinib 400 mg BID (n = 281) Imatinib 400 mg QD (n = 283) 5-yr follow-up Stratified by Sokal risk score Yr 1 Larson RA, et al. ASCO 2010. Abstract 6501. ENESTnd: Randomized Phase III Trial of Imatinib vs Nilotinib in Ph-Positive CP-CML ENESTnd: Primary Endpoint—MMR Rate at 12 Mos (ITT Population) Larson RA, et al. ASCO 2010. Abstract 6501. Saglio G, et al. N Engl J Med. 2010;[Epub ahead of print]. Reprinted with permission. 60 50 40 30 20 10 0 MMR (%) P .0001 P .0001 44 43 22 Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD n = 282 n = 281 n = 283 ENESTnd: CCyR Rates by 12 Mos and Overall (ITT) Among patients who had a cytogenetic assessment a